Since 1992 the availability of the criteria of systemic inflammatory response syndrome (SIRS) has improved the identification of subjects with sepsis. Sepsis remains a major hospital complication worldwide, responsible for thousands of deaths in children with cancer. Different biomarkers have been proposed for discrimination of septic child, who is not, but its introduction and routine use in control programs and surveillance has not been possible so far. The challenge in septic cancer remains valid subject and makes it a public health problem. The research accompanying the treatment of these children and introducing them, depend on their effectiveness, financing and universal availability of methods; but especially strategic planning based on that knowledge.